Pharmaceuticals News and Research

RSS

ARYx Therapeutics receives guidance in writing from FDA on tecarfarin

ARYx Therapeutics, Inc., a biopharmaceutical company, today announced that is has received guidance in writing from the U.S. Food and Drug Administration (FDA) confirming that the existing development pathway remains acceptable to seek regulatory approval of ARYx’s novel anticoagulant agent, tecarfarin (ATI-5923).

5 Jan 2010

Derma Sciences signs contract to produce finger bandages

Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a specialty medical device/pharmaceutical company focused on advanced wound care, has finalized a contract with a leading global healthcare products company to produce finger bandages

5 Jan 2010

PanGenex adds number of CAM practitioners to national physicians' referral network

PanGenex Corporation, a global nutraceutical and dietary supplement manufacturer and marketer, announced today it has added a number of complementary alternative medicine (CAM)/holistic medical practitioners to its national physicians' referral network.

5 Jan 2010

Despite economic downturn, Russia still represents a promising healthcare market

Despite uncertain economic environment, Russia still represents a promising healthcare market with strong potential for further growth.

5 Jan 2010

CRT&T presents unique approach to solve issues presented to pharmaceutical executives

The Clinical Research Trends and Technology Forum (CRT&T) presents a unique approach to solving the issues presented to pharmaceutical executives. CRT&T blends educational keynotes and roundtables focusing on standards of care, quality processes and workflow with exposure to the newest and most innovative technologies on the market through one-on-one business meetings and networking events.

5 Jan 2010

Physicians fail to provide pain treatment for fear of prescription drug abuse

Millions of Americans with significant or chronic pain associated with their medical problems are being under-treated as physicians increasingly fail to provide comprehensive pain treatment - either due to inadequate training, personal biases or fear of prescription drug abuse.

5 Jan 2010

Further stay of Cipher's NDA for CIP-TRAMADOL ER terminated

Cipher Pharmaceuticals Inc. today announced a final judgment (the "Cipher Judgment") has been entered in favour of Cipher in relation to pending patent litigation with Purdue Pharma Products L.P. and Napp Pharmaceutical Group Ltd. (together "Purdue") in the United States District Court for the Eastern District of Virginia (the "Court").

5 Jan 2010

Coformulation of rilpivirine and Truvada HIV drugs will achieve sales of more than $2 billion in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in 2018, the fixed dose coformulation of Tibotec's rilpivirine and Gilead's Truvada will achieve blockbuster sales of more than $2 billion in the HIV drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

5 Jan 2010

Significant opportunity for alternative ulcerative colitis biological therapy

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a biological therapy with a mechanism of action other than tumor necrosis factor alpha (TNF-alpha) inhibition for the treatment of moderate to severe ulcerative colitis, would earn a 25 percent patient share according to surveyed U.S. gastroenterologists. Similarly, in Europe, such an agent would also earn 25 percent patient share according to surveyed European gastroenterologists.

5 Jan 2010

Anti-inflammatory prescription drug reduces the risk of common skin cancer in humans

A widely-available anti-inflammatory prescription drug can reduce the risk of a common skin cancer in humans, according to a researcher at Stanford's School of Medicine.

5 Jan 2010

FDA approves generic donepezil hydrochloride orally disintegrating tablets

The U.S. Food and Drug Administration approved the first generic versions of Aricept (donepezil hydrochloride) orally disintegrating tablets on Dec. 11. Donepezil hydrochloride is indicated for the treatment of dementia related to Alzheimer's disease.

5 Jan 2010

Elusys Therapeutics signs contract to complete the final development of Anthim

Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company, announced today that it has signed a contract potentially totaling up to $143 million to complete the final development, commercial manufacturing and licensure of Anthim, the company's late stage anthrax therapeutic.

5 Jan 2010

CBI signs definitive share purchase agreement to acquire GL Biochem

Commonwealth Biotechnologies, Inc. (“CBI”) is pleased to announced it has entered into a revised and binding definitive share purchase agreement to acquire the parent of Shanghai-based GL

4 Jan 2010

Dicerna Pharmaceuticals and Kyowa Hakko Kirin sign research collaboration and license agreement

Dicerna Pharmaceuticals, Inc., (Dicerna) a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™ and Dicer Substrate siRNA (DsiRNA) molecules, and Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin), one of Japan's leading biopharmaceutical companies, announced today that the two companies have entered into a research collaboration and license agreement for the research, development and commercialization of drug delivery systems and DsiRNA pharmaceuticals for therapeutic targets in oncology.

4 Jan 2010

ADVENTRX Pharmaceuticals submits a NDA for its vinorelbine injectable emulsion

ADVENTRX Pharmaceuticals, Inc. announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate ANX-530 (vinorelbine injectable emulsion).

4 Jan 2010

Health risks of wooden pallet shipping platforms, call for Congress and FDA regulation

The expanded recall of TYLENOL Arthritis pain reliever is fresh evidence of the need for Congress and the FDA to regulate wood pallets used to transport food and pharmaceuticals in the United States because of the dangers they pose to human health.

4 Jan 2010

Novelos continues NOV-002 Phase 3 combination trial for lung cancer

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, is reporting Pfizer Inc. has announced that it has decided to discontinue the late-stage study of its lung cancer candidate figitumumab (CP-751,871) while Novelos' pivotal Phase 3 trial, with a primary efficacy endpoint of improvement in median overall survival, continues across approximately 12 countries and 100 clinical sites.

4 Jan 2010

China Yongxin Pharmaceuticals announces projected financial results for 2009

China Yongxin Pharmaceuticals, Inc., a leading manufacturer, distributor and retailer of Chinese traditional medicines, pharmaceutical products, natural health products, health food, cosmetics, and medical equipment in Northeastern China, today announced its projected financial results for the year ending December 31, 2009.

4 Jan 2010

Anika Therapeutics acquires Fidia Farmaceutici subsidiary FAB

Anika Therapeutics, Inc. today announced that it has acquired Fidia Advanced Biopolymers, s.r.l. (“FAB”), a wholly-owned subsidiary of privately held Italian pharmaceutical company, Fidia Farmaceutici S.p.A. FAB provides hyaluronic acid-based (“HA”) products in several therapeutic areas including for the regeneration of connective and structural tissues damaged by injuries, aging or degenerative diseases.

3 Jan 2010

D-Pharm commences enrollment in MACSI Phase III clinical study for acute ischemic stroke

D-Pharm Ltd announced enrollment of patients with acute ischemic stroke into its Phase III clinical study of DP-b99 (MACSI). The first patient has been enrolled at the Wolfson Medical Center, Israel. The MACSI trial involves numerous medical centers in the US, Canada, Europe, Israel, South Africa, South Korea and Brazil. DP-b99 is D-Pharm's most advanced product developed for protection of brain cells suffering from restricted blood and oxygen supply (ischemia).

3 Jan 2010

Pharmaceuticals News and Research

ARYx Therapeutics receives guidance in writing from FDA on tecarfarin

Derma Sciences signs contract to produce finger bandages

PanGenex adds number of CAM practitioners to national physicians' referral network

Despite economic downturn, Russia still represents a promising healthcare market

CRT&T presents unique approach to solve issues presented to pharmaceutical executives

Physicians fail to provide pain treatment for fear of prescription drug abuse

Further stay of Cipher's NDA for CIP-TRAMADOL ER terminated

Coformulation of rilpivirine and Truvada HIV drugs will achieve sales of more than $2 billion in 2018

Significant opportunity for alternative ulcerative colitis biological therapy

Anti-inflammatory prescription drug reduces the risk of common skin cancer in humans

FDA approves generic donepezil hydrochloride orally disintegrating tablets

Elusys Therapeutics signs contract to complete the final development of Anthim

CBI signs definitive share purchase agreement to acquire GL Biochem

Dicerna Pharmaceuticals and Kyowa Hakko Kirin sign research collaboration and license agreement

ADVENTRX Pharmaceuticals submits a NDA for its vinorelbine injectable emulsion

Health risks of wooden pallet shipping platforms, call for Congress and FDA regulation

Novelos continues NOV-002 Phase 3 combination trial for lung cancer

China Yongxin Pharmaceuticals announces projected financial results for 2009

Anika Therapeutics acquires Fidia Farmaceutici subsidiary FAB

D-Pharm commences enrollment in MACSI Phase III clinical study for acute ischemic stroke

Industry Focus - Biopharma eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence